Pharmacokinetics, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain; Centro de Investigación Lascaray ikergunea, University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain.
Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Navarra, Pamplona, Spain.
Int J Antimicrob Agents. 2015 May;45(5):504-11. doi: 10.1016/j.ijantimicag.2015.01.008. Epub 2015 Feb 16.
The antibiotics used for prophylaxis in colorectal surgery must maintain appropriate plasma concentrations during the entire surgery to avoid surgical site infections caused by aerobes and anaerobes; cefuroxime plus metronidazole is one of the combinations used. The aim of this study was to evaluate the adequacy of cefuroxime plus metronidazole administration as prophylaxis in colorectal surgery. In total, 63 patients electively undergoing rectal or colon surgery were administered 1500mg of cefuroxime and 1500mg of metronidazole in 15-min and 1-h infusions, respectively, prior to surgery. Blood samples were withdrawn during and after surgery for determination of plasma concentrations by high-performance liquid chromatography. Population pharmacokinetic models were developed using NONMEM 7.2.0. Pharmacokinetic/pharmacodynamic (PK/PD) simulations were performed to explore the ability of different dosage regimens to achieve the pharmacodynamic targets. Pharmacokinetics for both antibiotics were best described by a two-compartment model. Elimination of cefuroxime was conditioned by creatinine clearance (CLCr). The half-life of cefuroxime was 1.5h for patients with normal renal function and 4.9h in patients with renal impairment. Elimination and distribution of metronidazole were affected by patient body weight (BW). PK/PD analysis revealed that a single-dose protocol of 1500mg of cefuroxime and metronidazole is adequate in short surgeries (≤2h). However, for longer surgeries, recommendations are suggested depending on the patient's CLCr and BW. Additional doses of cefuroxime are needed for patients with moderate renal impairment or those presenting normal renal function. For metronidazole, an additional dose is needed for patients with a BW of 90kg.
在结直肠手术中,预防使用的抗生素必须在整个手术过程中保持适当的血浆浓度,以避免需氧菌和厌氧菌引起的手术部位感染;头孢呋辛加甲硝唑是其中一种联合用药。本研究旨在评估头孢呋辛加甲硝唑作为结直肠手术预防用药的适宜性。共有 63 例择期行直肠或结肠手术的患者,在手术前分别给予 1500mg 头孢呋辛和 1500mg 甲硝唑,15 分钟和 1 小时输注。在手术中和手术后采集血样,通过高效液相色谱法测定血浆浓度。使用 NONMEM 7.2.0 开发群体药代动力学模型。进行药代动力学/药效学(PK/PD)模拟,以探索不同剂量方案实现药效学目标的能力。两种抗生素的药代动力学均最佳地用两室模型描述。头孢呋辛的清除受肌酐清除率(CLCr)的影响。肾功能正常患者的头孢呋辛半衰期为 1.5 小时,肾功能不全患者的半衰期为 4.9 小时。甲硝唑的消除和分布受患者体重(BW)的影响。PK/PD 分析表明,对于手术时间≤2 小时的短手术,单次给予 1500mg 头孢呋辛和甲硝唑即可。但是,对于较长的手术,建议根据患者的 CLCr 和 BW 进行剂量调整。对于中度肾功能不全或肾功能正常的患者,需要额外给予头孢呋辛。对于体重为 90kg 的患者,需要额外给予甲硝唑。